Funding Awardees

The purpose of these Knight funding mechanisms is to cultivate outstanding translational cancer research by assisting in the generation of preliminary data leading to peer-reviewed national funding. This mechanism is intended to support clinical, basic, or population-based research that is cancer focused. 

Many of the awards below have been make possible as a result of the generous support of our philanthropic donors.

OHSU Knight Cancer Research Development Awards: 2014

This $10,000 one-year award cultivates outstanding cancer research by assisting in the generation of preliminary data for peer-reviewed national funding and career development proposals. This mechanism is intended to support clinical, basic or population-based research that is cancer-focused. Interdisciplinary research is encouraged.

Jacob HendersonJacob Henderson

House officer
Evaluating the oncogenic potential of TSC1/2 mutations and efficacy of MTOR inhibitors in pediatric medulloblastoma
Umpqua Bank's Innovation Award for Pediatric Cancer Research
 

Evan LindEvan Lind, Ph.D.

Assistant professor, molecular microbiology and immunology

Investigating the impact of inflammatory cytokines on Fanconi anemia hematopoietic stem cells during viral infection
Umpqua Bank's Innovation Award for Pediatric Cancer Research

 

No Photo AvailableBaotong Xie

Research assistant professor, integrative biosciences

Regulation of the hippo tumor suppressor pathway

 

terryTerry Medler, Ph.D.

Postdoctoral researcher, cell and developmental biology

Contribution of B cells to squamous carcinogenesis in a mouse model of Fanconi anemia

 

No Photo AvailableStephanie Krasnow, Ph.D.

Instructor, pediatrics

Hypothalamic Orexin in chemotherapy-induced fatigue

 

OHSU Knight Cancer Pilot Project Awards: 2014

This $50,000 one-year award is to assist in the cultivation of outstanding cancer research by assisting in the generation of preliminary data leading to peer-reviewed national funding. This mechanism is intended to support fundamental biologic mechanisms that underlie cancer initiation, progression or treatment. 

Hayes_LattinBrandon Hayes-Lattin, M.D.

Associate professor, hematology and medical oncology

Development of an AYA-specific transition program for cancer survivors
Adelina I. Paperini Estate

 

Sancy Leachman, MD, PhDSancy Leachman, M.D., Ph.D.; Jackie Shannon, Ph.D.

Professor and chair of dermatology; scientist, Institute of Occupational Health Sciences

Initiating a statewide war on melanoma
Adelina I. Paperini Estate

 

Laura Heiser, PhDLaura Heiser, Ph.D.; Xiaolin Nan, Ph.D.

Research assistant professor, biomedical engineering; assistant professor, biomedical engineering

Systems biology of RAS dimerization and oncogenesis
Brenden Colson Gift

 

Philip Stork, MDPhilip Stork, M.D.

Senior scientist, Vollum Institute

Identifying new drug targets to block KRas/Raf in pancreatic cancer
Brenden Colson Gift

 

Melissa Wong, PhDMelissa Wong, Ph.D.

Associate professor, cell and developmental biology

Brenden Colson Gift

 

Joshi Alumkal, MDJoshi Alumkal, M.D.; Paul Spellman, Ph.D.

Assistant professor, hematology and medical oncology; professor, molecular and medical genetics

Genetic variation in evolving prostate cancers as they develop enzalutamide resistance
Ann P Follansbee Estate

 

Peter Kurre, MDPeter Kurre, M.D.; Jeffrey Tyner, Ph.D.

Associate professor, Oregon Stem Cell Center; assistant professor, hematology and medical oncology

AML exosomes reprogram bone marrow stromal components toward extrinsic drug resistance
CCSG

 

Klaus Früh, PhDKlaus Früh, Ph.D.; Daniel Streblow, Ph.D.

Senior scientist, Vaccine and Gene Therapy Institute; Associate scientist, Vaccine and Gene Therapy Institute

CMV-vectored cancer vaccines
Prostate Foundation Funds

 

Matthew Taylor, MDMatthew Taylor, M.D.

Assistant professor, hematology and medical oncology

Mechanisms of tumor organotropism in metastatic melanoma
John D. Gray Fund for Melanoma Research

 

OHSU Knight Cancer Clinical Scholars: 2015

This program is a $25,000 one-year award that allows protected research time to leading clinical investigators to enable them to carry out innovative clinical research that advances the Institute's mission. It also advances discoveries to improve its detection, diagnosis, treatment and prevention.

Joshi Alumkal, M.D.Joshi Alumkal, M.D.

Assistant professor, hematology and medical oncology

 

Jeremy Cetnar, MD, MSHPRJeremy Cetnar, M.D., M.S.H.P.R.

Assistant professor, hematology and medical oncology

 

Lara Davis, M.D.Lara Davis, M.D.

Assistant professor, hematology and medical oncology

 

Michael Heinrich, M.D.Michael Heinrich, M.D.

Assistant professor, hematology and medical oncology

 

Eneida NemecekEneida Nemecek, M.D., M.S.

Director, Pediatric Blood and Marrow Transplantation Program

  

Christopher Ryan, MDChris Ryan, M.D.

Associate professor, hematology and medical oncology

 

scott_emma_smallEmma Scott, M.D.

Assistant professor, hematology and medical oncology

  

Matthew Taylor, M.D.Matthew Taylor, M.D.

Assistant professor, hematology and medical oncology

  

 Gina Vaccaro, MD Gina Vaccaro, M.D.

Associate professor, hematology and medical oncology